Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress will focus on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics. The agenda will address Chronic Myelogenous Leukemia (CML), Lymphomas, Plasma Cell Neoplasms, and supportive care and practice issues in hematologic malignancies.
|Physicians, Nurses, Pharmacists, and Other Health Care Professionals (not including Industry)||No Charge|
Register now for a special one-day session of NCCN Academy for Excellence & Leadership in Oncology™: School of Pharmaceutical & Biotech Business being held in conjunction with the NCCN 5th Annual Congress.